Measuring Adherence to Chronic Disease Treatment Using Dispensing Data: An Example from Thailand Sauwakon Ratanawijitrasin, PhD Sanita Hirunrassamee, PhD.

Slides:



Advertisements
Similar presentations
Cardiovascular Side Effects of HIV Treatment
Advertisements

TB & HIV Infection: Treatment
TB & HIV Infection: Treatment Your name Institution/organization Meeting Date International Standard 8, 13 TB & HIV Infection: Treatment Your name Institution/organization.
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.
HIV Situation in India Dr Sunil Gaikwad.
Development of ARV FDC for Pediatric use Alan Parr, Pharm.D., Ph.D. GlaxoSmithKline Research Triangle Park, NC.
Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD.
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Disease State Management The Pharmacist’s Role
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
FINANCING ARV EXPERIENCE FROM MALAYSIA BY SHA’ARI NGADIMAN, MD, MPH, EIP, AM MINISTRY OF HEALTH MALAYSIA.
HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.
MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.
Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
HIV and Psychiatric Medication Interactions
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
Adverse Reactions & Antiretroviral Therapy Kirsten B. Balano, PharmD October 26, 2002.
HIV/ AIDS Answers to your questions. What is HIV HIV- Human Immunodeficiency Virus HIV- Human Immunodeficiency Virus The virus attacks the T-Cells in.
Introduction to ARV therapy
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.
The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.
Medicines Patent Pool and Seychelles A primer For more information visit:
HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.
Bi Sheng Professor, Director Rehabilitation Medicine Center Chinese PLA General Hospital.
WHO - PSM 14/7/2005 Principles for selection of medicines Dr Mary R. Couper Quality Assurance and Safety of Medicines WHO.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Introductory talk D Costagliola.
Intellectual Property Law FDA Thailand Health Insurance in Thailand.
DOES YOUR HEALTHCARE DEPEND ON HOW YOUR INSURER PAYS PROVIDER? VARIATION IN UTILIZATION AND OUTCOEMS IN THAILAND Sanita Hirunrassamee, Ph.D. 1 and Sauwakon.
Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd – 28 th November 2009.
A Financing AIDS and pricing antiretrovirals (ARV): the Brazilian and Mexican case RAUL MOLINA GONZÁLEZ UNIVERSIDAD.
LIFE-SAVING JOURNEY, Dr.Krisana Kraisintu Thailand.
Current Concepts in HIV/AIDS A Pharmacy Perspective Carol Schneiderman, Pharm D Clinical Pharmacist, University of Arizona.
Anti-viral Drugs.. Introduction The viral agents kill viruses by inhibiting their ability to replicate, but there are currently only about a dozen such.
NYSDOH/AI The Role of Methadone in HIV Prevention And Treatment Sharon Stancliff, MD Medical Consultant AIDS Institute New York State Department of Health.
HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.
Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.
Ministry of Health Health Surveillance Secretariat NATIONAL STD/AIDS PROGRAMME.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.
Accessibility to Medicines Under Compulsory Licenses: Anti- HIV/AIDS (Efavirenz, Kaletra) and Clopidogrel Sub-committee for Benefits and Services Development.
AN OVERVIEW OF PHARMACOVIGILANCE OF HIV/AIDS IN NIGERIA
Integrated Care for Veterans with Diabetes & Serious Mental Illness Judith A. Long, MD Steven C. Marcus, PhD.
Retrovirus HIV (humans) Animal viruses resulting in cancer / AIDS 15-39%
© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.
Pharmacovigilance respect to ARV th 2009 White sand Hotel, Dar es salaam.
Phase 3 Treatment-Naïve and Treatment-Experienced
Chronic Non-Communicable Diseases
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Drug Pricing Policies and Challenges
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Cross-sectional assessment of patient outcomes using a systematic file review process: Results from 12,987 patient files Ambereen Jaffer, Gesine Meyer-Rath,
Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study
PSYCH 628 Enthusiastic Studysnaptutorial.com
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Pharmacovigilance in Uganda
Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.
School of Pharmacy, University of Nizwa
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Forecasting for ARVs medicines
Volume 42, Issue 3, Pages (March 2005)
Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of.
Presentation transcript:

Measuring Adherence to Chronic Disease Treatment Using Dispensing Data: An Example from Thailand Sauwakon Ratanawijitrasin, PhD Sanita Hirunrassamee, PhD

Why? I.E-dispensing data are routinely collected by health facilities. II.Use of e-dispensing database allows routine adherence monitoring  guide interventions for improving use of medicines. III.Data pool, if available, allows routine population level monitoring. IV.Quality indicators  performance evaluation

Objectives o To demonstrate the use of e-dispensing database collected by health facilities to monitor adherence in long term care o To identify technical and contextual challenges o To demonstrate the use of e-dispensing database collected by health facilities to monitor adherence in long term care o To identify technical and contextual challenges Applicability o o Medicines with high specificity for selected illness conditions

Specificity level HIV H DM H Hypertension L Glaucoma H Osteoporosis H Epilepsy M

Patient selection ICD-10 +med use Sp med Non Sp Med ICD-10 +med use Sp med

Na.valpoate inj. Phenytoin Phenobarbital Levtiracepam Migraine drug Topiramate Sod. Valpoate oral form Psychotic drug Lamotrigine Sod. Valpoate oral form Neuropathic pain drug Gabapentin Oxcarbazepine Carbamazepine

HIV drug Antiviral for Hep. B Lamivudine 100 mg 150 mg ABACAVIR ATAZANAVIR DIDANOSINE EFAVIRENZ INDINAVIR LOPINAVIR RITONAVIR NELFINAVIR NEVIRAPINE SAQUINAVIR STAVUDINE TENOFOVIR ZIDOVUDINE

# of patients identified by …. NO.OF PT.ICD-10 Pt from ICD-10 (using med.) Disp. Database HIV1, ,604 DM21,10010,74713,917 Glaucoma5,5192,5873,095 Epilepsy2,1491,1366,533

Company Logo Patient group

DATA POOL: no interhospital data pool APPOINTMENT DATA: not integrated DRUG CODE: diff codes for diff systems DOSAGE DATA: might not be available ICD-10 DATA: incomplete CHALLENGE s MEDICAL SHOPPING TREATMENT CHANGE